Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990181 | 0.86 | ALDH1A1 (0.50) | CYP19A1ALDH1A1MAOBKMT2AMAPT | |
| SCHEMBL11637817 | 0.85 | CYP19A1 (0.42) | CYP19A1ALDH1A1MAOBL3MBTL1TSHR | |
| SCHEMBL4729600 | 0.84 | HTT (0.43) | CYP19A1ALDH1A1MAOBL3MBTL1TSHR | |
| SCHEMBL4728950 | 0.84 | TDP2 (0.40) | CYP19A1ALDH1A1NPSR1KMT2AMAPT | |
| SCHEMBL4726332 | 0.84 | ALDH1A1 (0.39) | CYP19A1ALDH1A1L3MBTL1TSHRNPSR1 | |
| SCHEMBL2173756 | 0.84 | MAPT (0.39) | CYP19A1ALDH1A1MAOBL3MBTL1NPSR1 | |
| SCHEMBL2172143 | 0.83 | MAOB (0.48) | CYP19A1ALDH1A1MAOBTSHRKMT2A | |
| SCHEMBL2172568 | 0.83 | CYP19A1 (0.46) | CYP19A1ALDH1A1L3MBTL1NPSR1KMT2A | |
| SCHEMBL4727256 | 0.83 | CYP19A1 (0.50) | CYP19A1ALDH1A1KMT2AMAPT | |
| SCHEMBL9832882 | 0.82 | MAOB (0.47) | CYP19A1ALDH1A1MAOBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035356-A2 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| CN-100436445-C | Pyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| WO-2008035356-A2 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1759110-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0274443-B1 | HETEROARYL 3-OXO-PROPANENITRILE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-29 | — | — | EP | disclosed |
| US-4816467-A | BACTERICIDES, VIRICIDES | FARMITALIA CARLO ERBA S.R.L (IT) | 1989-03-28 | — | — | US | disclosed |
| EP-0274443-A1 | Heteroaryl 3-oxo-propanenitrile derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | CYP19A1 4216/4885ALDH1A1 4184/4885MAOB 3253/4885 |
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CYP19A1 2411/4885ALDH1A1 139/4885MAOB 1442/4885 |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | CHRNA7, CHRNA6, CHRNA5 | CYP19A1 2064/4885ALDH1A1 1722/4885MAOB 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.